Novartis (NOVN) 44th Annual J.P. Morgan Healthcare Conference summary

Financial performance and strategy

• Achieved strong sales and core operating income growth, with core operating margin reaching 38.7% in 2024 and targeting 40% by 2025, alongside 7% compound annual sales growth and 1,100 bps core margin expansion from 2019–2024.

• Generated $16.3 billion in free cash flow in 2024 and $16 billion in the first three quarters of 2025, with return on invested capital at 38.7% by 9M 2025.

• Ranked among top industry peers for total shareholder return, with 81% TSR over three years and 65% over five years.

• Capital allocation priorities include organic investment, value-creating bolt-ons, consistent dividend growth, and ongoing share buybacks, with $7.8bn in dividends in 2025 and a $15bn buyback completed, plus a new $10bn buyback underway.

• Maintains a strategy focused on four core therapeutic areas, advanced technology platforms, and four priority geographies: US, China, Germany, and Japan.

Pipeline and growth outlook

• Portfolio includes 14 in-market blockbusters, nine brands with multi-billion-dollar peak sales potential, six ongoing launches, and 30+ high-value pipeline assets.

• 15+ submission-enabling readouts expected in the next two years, entering a catalyst-rich period.

• Technology platforms target large markets: $36 billion for RNA therapeutics, $28 billion for radioligand therapies, and up to $50 billion for cell and gene therapies.

• Long-term guidance: high single-digit growth for 2024-2025, 5%-6% CAGR to 2030, and mid-single-digit growth beyond 2030, aiming for $60-80 billion in revenue by the mid-2030s.

• Eight potential multi-billion-dollar assets are expected to launch mid-term.

Commercial execution and product launches

• Successfully offsetting patent expiries with in-market growth and pipeline launches.

• Expects 1%-2% short-term margin dilution from the Avidity acquisition, returning to 40% margin by 2029.

• Strong commercial execution in the U.S. and internationally, with leading market shares for key brands.

• Peak sales guidance: Kisqali ($10B+), Scemblix ($4B+), Itivisma (multi-billion), Roxido (multi-billion potential in CSU and other indications).

• Multiple high-value pipeline assets, including Ianalumab and Pelabresib, with significant upcoming readouts.